Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More

Radius Health Reports Positive Topline Data from Ph. 3 Metastatic Breast Cancer Trial

  ()
Shares of Radius Health Inc. traded 17% higher after the firm reported positive topline results from the Phase 3 EMERALD study of elacestrant in ER+/HER2- advanced or metastatic breast cancer (mBC). read more >

Aquaculture Firm to Provide US Gulf Coast Distributor with 25,000 Pounds of Live Gourmet-Quality Shrimp

  ()
NaturalShrimp Inc.'s shares traded 12% higher after the company reported it entered into an agreement with Gulf Seafood Inc. for delivery of 25,000 lbs. of naturally grown, chemical and antibiotic-free, live shrimp. read more >

New French Vaccine May 'Play an Important Role in Overcoming' COVID-19

  ()
Valneva SE shares traded 40% higher after the company reported positive results from its Phase 3 clinical trial of its COVID-19 vaccine candidate, VLA2001. The firm claimed that VLA2001 produced superior neutralizing antibody titer levels compared to AstraZeneca's AZD1222 (ChAdOx1-S) vaccine in the study. read more >

DarioHealth Contracts With National Health Plan to Offer Behavioral Health Services to Millions of Members

  ()
DarioHealth Corp. shares traded 17% higher after the company reported it entered into an agreement with an unnamed national healthcare provider to make its behavioral health products available to millions of the plan's members. read more >

Company Releases iOS-Based App for Cannabis Purchase and Delivery

Research Report
  ()
The potential is "enormous" for Stem Holdings Inc. dba Driven By Stem's new app, Budee Cannabis Delivery, given it is available in the Apple App Store, a Noble Capital Markets report noted. read more >

Pacira Bids to Acquire Flexion to Expand Leadership Position in Non-Opioid Pain Management

  ()
Flexion Therapeutics Inc. shares traded 60% higher after the company reported it entered into a definitive agreement to be acquired by Pacira BioSciences Inc. for $8.00 per share in cash plus an additional non-tradeable contingent value right worth up to $8.00 per share in cash if five specific milestones are met. read more >

ChemoCentryx Shares Double After FDA Approves TAVNEOS™ for Treatment of ANCA-Associated Vasculitis

  ()
Shares of ChemoCentryx Inc. traded 96% higher after the company reported the U.S. FDA approved its orally administered TAVNEOS™ (avacopan) for use in treatment of ANCA-associated vasculitis, a systemic autoimmune disease that often results in kidney or other major organ damage and failure that can be fatal if left untreated. read more >

Merus Shares Rise 37% After Firm Presents Multiclonic Antibodies Clinical Data to Molecular Targets & Cancer Therapeutics Summit

  ()
Merus NV shares traded higher after the company presented early and preclinical data for two full-length, multispecific antibodies, MCLA-158 and zenocutuzumab, to the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. read more >

Voyager Shares Lift Off After Firm Signs License Deal With Pfizer for Next-Gen AAV Capsids for Gene Therapy Programs

  ()
Shares of Voyager Therapeutics Inc. traded 51% higher after the company reported it entered into a license and option agreement with Pfizer Inc. for two of its TRACERᵀᴹ AAV capsids that will be utilized to enhance Pfizer's neurologic and cardiovascular gene therapy programs. Voyager will receive an upfront payment of $30 million and is eligible to receive up to $600 million more plus product sales-based royalties, if all options are exercised and certain milestones are achieved. read more >

Reliq's Telemedicine Platform Helps Free Up Hospital Space for COVID-19 Delta Patients

  ()
Simultaneously, demand is growing for Reliq Health's iUGO Care software as virtual healthcare delivery increases during the COVID-19 pandemic. read more >

SmileDirectClub Granted Patent for Mobile Oral Care Bus to Serve Remote Regions in the US & UK

  ()
SmileDirectClub Inc. shares traded 15% higher after the company reported that the U.S. Patent & Trademark Office has allowed its new patent for the firm's mobile SmileBus concept whereby its SmileShop on wheels is mobilized to expand access to convenient, affordable oral care in remote areas across the U.S. and the U.K. read more >

Xenon Pharma Shares Gain 80% on Positive Data in Phase 2b Focal Epilepsy Trial

  ()
Shares of Xenon Pharmaceuticals Inc. soared to a new 52-week high after the company reported topline data from its Phase 2b X-TOLE clinical study demonstrating that its epilepsy drug candidate XEN1101 successfully met several primary and secondary efficacy endpoints and decreased monthly focal seizure frequency by 50% or greater from baseline. read more >

Merck and Ridgeback Post Interim Data From Phase 3 Antiviral Drug Trial Showing 50% Reductions in Hospitalizations and Deaths in Mild and Moderate COV

  ()
Shares of Merck & Co. Inc. traded 9% higher after the company reported that in a global Phase 3 clinical trial conducted together with its partner Ridgeback Biotherapeutics, oral antiviral molnupiravir reduced risk of hospitalization or death by 50% versus placebo in patients with mild or moderate COVID-19. Merck plans to submit an Emergency Use Authorization application to the U.S. FDA and if authorized it would make molnupiravir the first approved oral antiviral medicine for COVID-19. read more >

Expert Investing Ideas

"STEM continued to build momentum during Q3 FY21."

–Joseph Gomes, Noble Capital Markets


"AGN is switching focus to the IPF/chronic cough indication."

–André Uddin, Research Capital Corporation


"STEM will benefit from strong wholesale sales trends."

–Jonathan DeCourcey, Viridian Capital Advisors


"AGN requested a meeting with the FDA to discuss advancing ifenprodil."

–André Uddin, Research Capital Corporation


"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

–André Uddin, Research Capital Corporation


"AGN is to continue a number of preclinical studies of DMT for stroke."

–André Uddin, Research Capital Corporation


"AGN [shares] are now in a vigorous uptrend."

–Clive Maund, CliveMaund.com


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Coverage Initiated on Nanomedicine Firm, Upside 'Potentially Significant' With Upcoming Trial Results

Research Report
  ()
"With Clene's potential to realize several multibillion-dollar revenue opportunities, we see its roughly $480 million enterprise value as offering attractive risk-reward," an Oppenheimer report noted. read more >

COVID-19 Vaccine Could Be Approved in Q4/21 for 5 to 11 Year Olds

Research Report
  ()
"Label extension for BioNTech and Pfizer's Comirnaty [vaccine] to include use in these younger individuals ought to buoy revenue growth near term," noted an H.C. Wainwright & Co. report. read more >

Alzamend Shares Rise After FDA Gives Positive Response to Pre-IND Filing for Immune-Boosting Alzheimer's Vaccine

  ()
Shares of Alzamend Neuro Inc. traded 36% higher after the company reported that the U.S. FDA responded favorably to its Pre-IND application for AL002, a cell-based therapeutic vaccine designed to restore patients' immunological systems, providing them with the ability to combat Alzheimer's Disease. The FDA has granted the firm approval to initiate a combined Phase 1/2 clinical trial in Q1/22. read more >

Biopharma Expands Clinical Program of Lead Drug Candidate to Treat Chronic Cough

  ()
Algernon Pharmaceuticals will now pursue Ifenprodil in chronic cough based on encouraging recent study results in a Phase 2 trial. read more >

Cannabis Firm Expands Footprint in Central California With New Distribution Center

Research Report
  ()
"The expansion is expected to drive topline sales with greater efficiency," noted a Noble Capital Markets report. read more >

Telemedicine Tech Firm Poised to Generate $11 Million of Revenue

  ()
Reliq Health Technologies signs contracts with three new clients for its proprietary remote healthcare delivery and care tracking platform, which has particularly significant implications during the era of the COVID-19 pandemic. read more >